总部位于肯塔基州的3D生物打印公司Koligo Therapeutics(ASX:KOL) is due to list on theAustralian Securities Exchangeat the end of March through an首次公开募股（IPO）。
Koligo希望提高AUD $ 7米20 c share from the IPO, establishing a market value of approximately AUD$22m. Koligo will use the funds raised through the IPO to expand its manufacturing capacity and drive sales into targeted hospitals, so that medical treatments can utilise Koligo technology. Furthermore, Koligo is looking to take advantage of opportunities for international growth, and to develop its patented 3D-V technology platform and product pipeline.
马修·雷曼（Matthew Lehman）, CEO of Koligo, explains, “Our listing on the ASX will accelerate Koligo’s growth and improve our ability to make a real difference in patients’ lives who suffer these debilitating conditions. The local market understands the value these companies provide.我们对ASX上其他再生医学和细胞疗法公司的成功感到高兴，例如外卖药物，多诺沃和cynata。”
Engineering tissue and cell transplantation with 3D bioprinting
Koligo’s 3D-V bioprinting platform is intended to develop and improve its regenerative medicine products and engineer cell and tissue transplantation with 3D bioprinting technology. The 3D bioprinted products are planned for commercial release and will be used to treat serious health conditions and disorders such as pancreatitis, type 1 diabetes, liver failure and more. An example of Koligo’s 3D bioprinting processes includes Stylescel-L, where a 3D bioprinted spheroid is injected into patients to allow better oxygen and blood flow. Lehman adds:
“ Koligo将使用我们的3D-V Bio印刷转换人类细胞和组织移植。我们将创建3D可生物降解的生物印刷的球体，其中包含患者的基质血管分数细胞和/或微血管碎片和胰岛胰岛[…]这些球体“脚手架”允许在移植和安全生物降解后改善细胞或组织的功能。”
Koligo is also committed to the wide distribution of pancreatic islets, which are the cells that produce insulin in the pancreas. The company distributes the islets as part of its Kyslecel product, to help treat pancreatitis, a condition resulting in the inflammation of the pancreas. Koligo partners with hospitals to remove and transfer a patient’s pancreas to its FDA-registered labs. The pancreatic islets are then preserved into ‘Kyslecel’, and sent back to hospitals to be implanted into the patient’s liver, in order to regulate blood sugar levels and treat the condition.
该公司正处于收入阶段，其Kyslecel产品在美国有资格出售。Koligo估计，Kyslecel在美国拥有3亿澳元的年度通讯市场，该产品已经从有限数量的医院客户那里获得了14个月的Koligo收入160万美元的Koligo收入。到2019年中，Koligo旨在释放Kyslecel v2.0，该V2.0将保持改善的货架寿命，从而为进一步的地区和可能的国际分配提供了长时间的运输时间。凭借Kyslecel v2.0，Koligo估计美国市场规模为每年6亿美元，该公司计划也进入印度和中国市场。
“The location of the Koligo lab is key as Louisville, Kentucky is also the home of the UPS Worldport hub with 318 flights daily and the capability for critical shipments of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCTPs). Based on initial success of Kyslecel™, Koligo will scale production and distribution to deliver patients access to this procedure at more hospitals across the United States.”
3D生物打印的一步
Koligo’s IPO and listing on the ASX represents the latest advancement for the commercialization of 3D bioprinting.
总部位于芝加哥BIOLIFE4D，另一家提出的生物技术公司IPO为5000万美元in September 2017, successfully demonstrated the ability to3D打印人类心脏组织2018年6月。该公司最终希望成为3D打印阀，血管，微型器官和全人心。
此外，总部位于加利福尼亚的3D生物打印公司Organovo Holdings Incis due to meet with the Food and Drug Administration (FDA) this year on its development of3D bioprinted tissuesfor the treatment of liver diseases. In 2016 the company previously suggests that its3D生物打印肝组织可以到2019年到达FDA。
Subscribe to the3D打印行业通讯for the latest news in additive manufacturing. You can also keep connected by following us onTwitter并喜欢我们Facebook。
寻找添加剂制造业的职业？访问3D Printing Jobsfor a selection of roles in the industry.
Featured image shows Koligo’s 3D-V technology. Screengrab via Koligo.
